Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025AVA6103 IND-enabling studies underway with a Phase 1 trial ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Researchers discovered lariocidin, a lasso peptide antibiotic that kills multidrug-resistant bacteria by binding a novel ...

Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the ...

Although peptide-based therapies tend to be extremely effective ... "We're also expanding this technology to make antibody ...

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company ...

Researchers from Cybrexa Therapeutics Inc. presented new preclinical data on CBX-15, a peptide-drug conjugate (PDC) consisting of a pH-low insertion peptide (pHLIP) linked to monomethyl auristatin E ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

MGC026, which is a TOP1i-based ADC, is undergoing a phase 1 dose-escalation study in patients with advanced solid tumors. The ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.